Company intelligence / Profile preview

Hematris Wound Care

Holzkirchen, Bavaria, Germanyhematris.de ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Hematris Wound Care is a German medical technology company that specializes in the development of innovative products for hemostasis and wound healing. Founded in 2011 and headquartered in Holzkirchen, the company focuses on utilizing chitosan-based biomaterials to create effective solutions for managing surgical bleeding and chronic wounds. Their product portfolio, which includes ScuHeal, ScuGel, and ScuFleece, is designed to provide rapid hemostasis and support the natural healing process across various clinical applications. In May 2019, Hematris was acquired by Aesculap AG, a subsidiary of B. Braun, to strengthen their global surgical product offerings.

Therapeutic areas: HematologyDermatology
Modalities: Device
Industry: Consumable Medical Devices

Partnerships

Aesculap

Beyond the preview

Go deeper on Hematris Wound Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hematris Wound Care.

Explore the full profile